https://orcid.org/0000-0001-7213-5949
References
- Inoue K, Komori R, Kunimatsu-Sanuki S, Ishida K, Tomita G. Frequency of use of fixed-combination eye drops by patients with glaucoma at multiple private practices in Japan. Clin Ophthalmol. 2022;16:557–565. doi:10.2147/OPTH.S345944
- Onoe H, Hirooka K, Nagayama M, et al. The efficacy, safety, and satisfaction associated with switching from brinzolamide or brimonidine to brinzolamide/brimonidine in open-angle glaucoma patients. J Pers Med. 2022;12(12):2057. doi:10.3390/jpm12122057
- Aoki R, Terao E, Dote S, et al. Efficacy and safety of a fixed combination of 1% brinzolamide and 0.1% brimonidine as treatment for glaucoma: a retrospective study focusing on the number of ingredients. BMJ Open Ophthalmol. 2022;7(1):e001200. doi:10.1136/bmjophth-2022-001200
- Sharma S, Trikha S, Perera SA, Aung T. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2015;9:2201–2207. doi:10.2147/OPTH.S72380
- Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S; Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151(4):671–681. doi:10.1016/j.ajo.2010.09.026
- Tanihara H, Kakuda T, Sano T, Kanno T, Kurihara Y. Long-term intraocular pressure-lowering effects and adverse events of ripasudil in patients with glaucoma or ocular hypertension over 24 months. Adv Ther. 2022;39(4):1659–1677. doi:10.1007/s12325-021-02023-y
- Sakamoto E, Ishida W, Sumi T, et al. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic solution clinical trial. Sci Rep. 2019;9(1):3755. doi:10.1038/s41598-019-40255-9
- Tanihara H, Yamamoto T, Aihara M, et al. Ripasudil–brimonidine fixed-dose combination vs ripasudil or brimonidine: two Phase 3 randomized clinical trials. Am J Ophthalmol. 2023;248:35–44. doi:10.1016/j.ajo.2022.11.017
- Tanihara H, Yamamoto T, Aihara M, et al. Crossover randomized study of pharmacologic effects of ripasudil-brimonidine fixed-dose combination versus ripasudil or brimonidine. Adv Ther. 2023;40(8):3559–3573. doi:10.1007/s12325-023-02534-w
- Djafari F, Lesk MR, Harasymowyczet J, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18(3):238–243. doi:10.1097/IJG.0b013e3181815421
- Inoue K, Kunimatsu-Sanuki S, Ishida K, Tomita G. Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications. Jpn J Ophthalmol. 2022;66(5):440–446. doi:10.1007/s10384-022-00930-3
- Kikuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. The Japan glaucoma society guidelines for glaucoma. Jpn J Ophthalmol. 2023;67(2):189–254. doi:10.1007/s10384-022-00970-9
- Inoue K, Kawashima T, Katakura S, et al. Switching from concomitant therapy to tafluprost/timolol fixed combination. Clin Ophthalmol. 2018;12:549–554. doi:10.2147/OPTH.S150595
- Inoue K, Okayama R, Higa R, Wakakura M, Tomita G. Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination. Clin Ophthalmol. 2012;6:607–612. doi:10.2147/OPTH.S30611
- Inoue K, Setogawa A, Higa R, Moriyama R, Wakakura M, Tomita G. Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs. Clin Ophthalmol. 2012;6:231–235. doi:10.2147/OPTH.S29062